Piper Jaffray & Co. downgrades Biogen Idec (Nasdaq: BIIB) from Market Perform to Underperform with a $65 price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE